The Legacy Institutional Biosafety Committee (IBC) is responsible for the review and approval of all research involving recombinant or synthetic nucleic acid molecules (e.g., rDNA) that utilize Legacy Research Institute facilities, and is available to provide review and approval for this type of research that utilizes any Legacy Health facility, resource or patients.

This oversight includes laboratory rDNA research and human gene therapy research. The IBC reviews all research projects at the Legacy Research Institute that involve non-recombinant risk groups 1 and 2 only. All other risk groups are not allowed to operate in LRI spaces.

Currently LRI IBC meets the 1st, 2nd, and 3rd quarters of the year, with the option of special scheduled meetings for rapid approval needs. The potential for ad hoc physical tours of LRI spaces by the IBC members occurs in the 4th quarter.

Instructions for starting the IBC review process:

• Request an IBC Protocol application form from the research laboratory safety specialist at msmoot@lhs.org. She will forward the required form(s) and instructions.
• Complete the form and have it signed by the principal investigator (PI).
• Return the form to the research laboratory safety specialist.

If you require guidance for completing the form, please contact the research laboratory safety specialist.

Note that human gene therapy research is also subject to IRB oversight, and the agent used requires prior FDA approval.

IBC Contact: Peggy Smoot, Research Laboratory Safety Specialist
Telephone: (503) 413-5409
Email: msmoot@lhs.org

Resources:

1. NIH Office of Science Policy (OSP)
2. NIH Guidelines for Research Involving Recombinant & Synthetic Nucleic Acids

Meeting Minutes:

• Coming Soon